Component

Circulating lycopene concentration

Circulating lycopene concentration. Species, exposure and limitations are retained in each linked claim.

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Co-dosing beta-carotene increased the 24-hour lycopene AUC relative to lycopene alone.

    All-trans-beta-carotene → Circulating lycopene concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/lycopene-research/9278568.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e318f6fef0bfed88403fa2adf46f9713ebddfe6ea586c29614e820442c57d056", "start_char": 0, "end_char": 1510, "text_sha256": "e318f6fef0bfed88403fa2adf46f9713ebddfe6ea586c29614e820442c57d056"}
    experimental_model
    Randomized-order double-blind crossover dosing experiment
    exposure
    60 mg beta-carotene, 60 mg lycopene, or 60 mg of each together
    limitations
    Acute high-dose study; does not justify routine co-supplementation or establish universal competition rules.
    nutrient_topic
    Lycopene research collection; topical membership is not evidence of a direct dietary effect. · Lycopene
    organism
    Human, ten healthy men
    plain_language
    Two carotenoids did not simply block one another in this experiment.
    primary_references
    [lycopene-p9278568] Ingestion by men of a combined dose of beta-carotene and lycopene does not affect the absorption of beta-carotene but improves that of lycopene. (1997). https://pubmed.ncbi.nlm.nih.gov/9278568/ DOI: 10.1093/jn/127.9.1833
    tissue_or_cell_type
    Serum carotenoid AUC over 24 hours

    Lycopene: absorption, metabolism, nutrient connections and human outcomes (2026-09-17) · lines 780–791

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized-order double-blind crossover dosing experiment · source_derived_draft · unverified_draft

    ### lycopene-beta-carotene-co-dose Co-dosing beta-carotene increased the 24-hour lycopene AUC relative to lycopene alone. Condition category: normal nutrient_topic: Lycopene research collection; topical membership is not evidence of a direct dietary effect. plain_language: Two carotenoids did not simply block one another in this experiment. organism: Human, ten healthy men tissue_or_cell_type: Serum carotenoid AUC over 24 hours experimental_model: Randomized-order double-blind crossover dosing experiment limitations: Acute high-dose study; does not justify routine co-supplementation or establish universal competition rules. exposure: 60 mg beta-carotene, 60 mg lycopene, or 60 mg of each together evidence_span: {"source_cache": "artifacts/lycopene-research/9278568.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e318f6fef0bfed88403fa2adf46f9713ebddfe6ea586c29614e820442c57d056", "start_char": 0, "end_char": 1510, "text_sha256": "e318f6fef0bfed88403fa2adf46f9713ebddfe6ea586c29614e820442c57d056"} [lycopene-p9278568] Ingestion by men of a combined dose of beta-carotene and lycopene does not affect the absorption of beta-carotene but improves that of lycopene. (1997). https://pubmed.ncbi.nlm.nih.gov/9278568/ DOI: 10.1093/jn/127.9.1833
    Complete structured claim and evidence

  2. Serum lycopene rose 0.55 micromolar with tomato extract and fell 0.29 micromolar with placebo.

    Lycopene → Circulating lycopene concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/lycopene-research/26422197.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1327af281ec573be44c88b10fc7973e82e4963aab7bef3f7d14122e6c2a3dbea", "start_char": 0, "end_char": 1542, "text_sha256": "1327af281ec573be44c88b10fc7973e82e4963aab7bef3f7d14122e6c2a3dbea"}
    experimental_model
    Randomized six-month repeat-biopsy trial
    exposure
    Tomato extract containing 30 mg/day lycopene versus placebo
    limitations
    Small surrogate-endpoint study; exploratory histological extent findings were not established cancer prevention.
    nutrient_topic
    Lycopene research collection; topical membership is not evidence of a direct dietary effect. · Lycopene
    organism
    Human, 58 completers with high-grade prostatic intraepithelial neoplasia
    plain_language
    The intervention clearly changed exposure.
    primary_references
    [lycopene-p26422197] A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia. (2015). https://pubmed.ncbi.nlm.nih.gov/26422197/ DOI: 10.1080/01635581.2015.1075560
    tissue_or_cell_type
    Serum biomarkers and prostate biopsies

    Lycopene: absorption, metabolism, nutrient connections and human outcomes (2026-09-17) · lines 1118–1129

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized six-month repeat-biopsy trial · source_derived_draft · unverified_draft

    ### lycopene-hgp-serum Serum lycopene rose 0.55 micromolar with tomato extract and fell 0.29 micromolar with placebo. Condition category: normal nutrient_topic: Lycopene research collection; topical membership is not evidence of a direct dietary effect. plain_language: The intervention clearly changed exposure. organism: Human, 58 completers with high-grade prostatic intraepithelial neoplasia tissue_or_cell_type: Serum biomarkers and prostate biopsies experimental_model: Randomized six-month repeat-biopsy trial limitations: Small surrogate-endpoint study; exploratory histological extent findings were not established cancer prevention. exposure: Tomato extract containing 30 mg/day lycopene versus placebo evidence_span: {"source_cache": "artifacts/lycopene-research/26422197.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1327af281ec573be44c88b10fc7973e82e4963aab7bef3f7d14122e6c2a3dbea", "start_char": 0, "end_char": 1542, "text_sha256": "1327af281ec573be44c88b10fc7973e82e4963aab7bef3f7d14122e6c2a3dbea"} [lycopene-p26422197] A Phase II Randomized Trial of Lycopene-Rich Tomato Extract Among Men with High-Grade Prostatic Intraepithelial Neoplasia. (2015). https://pubmed.ncbi.nlm.nih.gov/26422197/ DOI: 10.1080/01635581.2015.1075560
    Complete structured claim and evidence

  3. Intestinal SR-BI-overexpressing mice had approximately tenfold higher plasma lycopene than wild-type controls.

    Mouse scavenger receptor class B type I / Scarb1 → Circulating lycopene concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/lycopene-research/18641187.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7c71fd4fd3be9d14176bceb3c2104143269a788587feec232350a6f1c5913e3d", "start_char": 0, "end_char": 1557, "text_sha256": "7c71fd4fd3be9d14176bceb3c2104143269a788587feec232350a6f1c5913e3d"}
    experimental_model
    Transporter inhibition in Caco-2 cells; intestinal SR-BI transgenic mice
    exposure
    All-E and 5Z lycopene; mice received 0.25 g/kg diet for one month
    limitations
    Partial uptake inhibition is not proof of a sole transporter. Ezetimibe result is a cell assay, not a clinical drug-interaction trial.
    nutrient_topic
    Lycopene research collection; topical membership is not evidence of a direct dietary effect. · Lycopene
    organism
    Mouse
    plain_language
    Changing the uptake machinery changed blood exposure in mice.
    primary_references
    [lycopene-p18641187] Lycopene absorption in human intestinal cells and in mice involves scavenger receptor class B type I but not Niemann-Pick C1-like 1. (2008). https://pubmed.ncbi.nlm.nih.gov/18641187/ DOI: 10.1093/jn/138.8.1432
    tissue_or_cell_type
    Intestinal epithelium and plasma

    Lycopene: absorption, metabolism, nutrient connections and human outcomes (2026-09-17) · lines 130–141

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Transporter inhibition in Caco-2 cells; intestinal SR-BI transgenic mice · source_derived_draft · unverified_draft

    ### lycopene-mouse-srbi Intestinal SR-BI-overexpressing mice had approximately tenfold higher plasma lycopene than wild-type controls. Condition category: normal nutrient_topic: Lycopene research collection; topical membership is not evidence of a direct dietary effect. plain_language: Changing the uptake machinery changed blood exposure in mice. organism: Mouse tissue_or_cell_type: Intestinal epithelium and plasma experimental_model: Transporter inhibition in Caco-2 cells; intestinal SR-BI transgenic mice limitations: Partial uptake inhibition is not proof of a sole transporter. Ezetimibe result is a cell assay, not a clinical drug-interaction trial. exposure: All-E and 5Z lycopene; mice received 0.25 g/kg diet for one month evidence_span: {"source_cache": "artifacts/lycopene-research/18641187.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7c71fd4fd3be9d14176bceb3c2104143269a788587feec232350a6f1c5913e3d", "start_char": 0, "end_char": 1557, "text_sha256": "7c71fd4fd3be9d14176bceb3c2104143269a788587feec232350a6f1c5913e3d"} [lycopene-p18641187] Lycopene absorption in human intestinal cells and in mice involves scavenger receptor class B type I but not Niemann-Pick C1-like 1. (2008). https://pubmed.ncbi.nlm.nih.gov/18641187/ DOI: 10.1093/jn/138.8.1432
    Complete structured claim and evidence

  4. Olestra lowered serum lycopene by 12 weeks, persisting after cholesterol or BMI adjustment; the multivitamin did not prevent this.

    Olestra sucrose polyester mixture → Circulating lycopene concentration source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_span
    {"source_cache": "artifacts/lycopene-research/15930452.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "3a90148eb83ff18442e37f9fd5ed31f44acbf8d7616ef05ff1e65e6e2d64e84f", "start_char": 0, "end_char": 1595, "text_sha256": "3a90148eb83ff18442e37f9fd5ed31f44acbf8d7616ef05ff1e65e6e2d64e84f"}
    experimental_model
    Randomized 36-week controlled diet study
    exposure
    Olestra substituted for one-third of fat energy; daily multivitamin and vitamin-E-fortified olestra
    limitations
    Exposure-specific depletion, not an established lycopene deficiency syndrome; reference-range limits are not clinical deficiency thresholds.
    nutrient_topic
    Lycopene research collection; topical membership is not evidence of a direct dietary effect. · Lycopene
    organism
    Human, 37 healthy men
    plain_language
    Replacing dietary fat with a nonabsorbed substitute changed carotenoid exposure.
    primary_references
    [lycopene-p15930452] Daily intake of multivitamins during long-term intake of olestra in men prevents declines in serum vitamins A and E but not carotenoids. (2005). https://pubmed.ncbi.nlm.nih.gov/15930452/ DOI: 10.1093/jn/135.6.1456
    tissue_or_cell_type
    Serum carotenoids and fat-soluble vitamins
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    Lycopene: absorption, metabolism, nutrient connections and human outcomes (2026-09-17) · lines 858–869

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized 36-week controlled diet study · source_derived_draft · unverified_draft

    ### lycopene-olestra-lycopene Olestra lowered serum lycopene by 12 weeks, persisting after cholesterol or BMI adjustment; the multivitamin did not prevent this. Condition category: biomarker_context nutrient_topic: Lycopene research collection; topical membership is not evidence of a direct dietary effect. plain_language: Replacing dietary fat with a nonabsorbed substitute changed carotenoid exposure. organism: Human, 37 healthy men tissue_or_cell_type: Serum carotenoids and fat-soluble vitamins experimental_model: Randomized 36-week controlled diet study limitations: Exposure-specific depletion, not an established lycopene deficiency syndrome; reference-range limits are not clinical deficiency thresholds. exposure: Olestra substituted for one-third of fat energy; daily multivitamin and vitamin-E-fortified olestra evidence_span: {"source_cache": "artifacts/lycopene-research/15930452.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "3a90148eb83ff18442e37f9fd5ed31f44acbf8d7616ef05ff1e65e6e2d64e84f", "start_char": 0, "end_char": 1595, "text_sha256": "3a90148eb83ff18442e37f9fd5ed31f44acbf8d7616ef05ff1e65e6e2d64e84f"} [lycopene-p15930452] Daily intake of multivitamins during long-term intake of olestra in men prevents declines in serum vitamins A and E but not carotenoids. (2005). https://pubmed.ncbi.nlm.nih.gov/15930452/ DOI: 10.1093/jn/135.6.1456
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards